Netherlands' Qiagen Q2 sales flat, exceed company outlook

QIAGEN

05/08/2026 21:17

Overview
Netherlands molecular diagnostics firm's Q2 net sales flat yr/yr, exceeding company outlook
Adjusted diluted EPS for Q2 rose above company forecast
Company reaffirmed full-year 2026 outlook for modest sales and EPS growth

Outlook
Qiagen reaffirms 2026 net sales growth outlook of about 1-2% CER
Company maintains 2026 adjusted diluted EPS guidance of at least $2.43 CER
Qiagen expects stronger growth in second half of 2026, supported by new product launches

Result Drivers
GROWTH PILLARS - Sample technologies, QIAcuity and QIAGEN Digital Insights delivered solid sales growth, with Sample technologies leading gains in consumables and instruments
QUANTIFERON DEMAND - QuantiFERON sales rose slightly, but growth was limited by a significant decline in U.S. immigration testing demand
NEW PRODUCT LAUNCHES - Rollout of new sample preparation systems and QIAcuity gene expression kits contributed to momentum, according to CEO Thierry Bernard

Company press release: ID:nBw1ktrNMa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
 
$535 mln
 
Q2 Adjusted EPS
 
$0.62
 
Q2 EPS
 
$0.50
 
Q2 Adjusted Operating Income Margin
 
29.40%
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for QIAGEN N.V. is €40.00, about 10% above its August 5 closing price of €36.37
The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 13 three months ago

Reuters Recommended Reads
Aug 4 - Revvity Q2 revenue beats estimates on diagnostics growth
Aug 4 - Bio-Rad Q2 revenue beats analyst estimates on clinical diagnostics growth
Aug 5 - Charles River lifts profit forecast on improving biotech demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)